Atlas market file · Equity · United States
Ping An Biomedical Co., Ltd.PASW
- Last close
- 0.131
- Change
- +1.55%
- 96-bar range
- 0.11 – 0.214
- As of
- 6 Aug 2026
Ping An Biomedical Co., Ltd. is an apparel & other finishd prods of fabrics & similar matl issuer listed as PASW on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
PASW
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 57 weekly closes (-96.03% over the window).
Source rail: Yahoo Finance chart API (PASW). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for PASW. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
PASW public profile
Apparel & other finishd prods of fabrics & similar matl issuer. Ping An Biomedical Co., Ltd. is connected to current market context, cited company sources and its retained research file.
Ping An Biomedical Co., Ltd. trades as PASW on NASDAQ. Ping An Biomedical Co., Ltd. (PASW) has a latest verified close of 0.131, up 1.55%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files PASW under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Ping An Biomedical Co., Ltd. today
Ping An Biomedical (PASW) kicked off the week with a strategic cooperation agreement with Yuan Sheng Mei Yan, announced via 6-K filing on July 22, 2026. The deal, framed as a milestone for its biomedical innovation pipeline, arrives amid financials that suggest the company might need more than partnership photo ops to stay solvent. Revenues for the period ending September 30, 2025, totaled just $4.8M, with a net loss of $1.8M and a staggering $902,902 cash burn from operations.
At its core, PASW operates in the biomedical sector, but its latest filings paint a company stretched thin. Assets of $9.6M and liabilities of $3.3M leave equity at $6.4M, yet cash reserves are a mere $164,697-a figure that raises eyebrows when paired with an inventory build of $43,331. The question lingers: Is this preparation for growth, or a slow-motion inventory pile-up in a warehouse no one’s renting?
Financial red flags abound. The diluted EPS of -$0.10 and 18.5M shares outstanding highlight dilution risks, while insider ownership filings from April 2026 reveal a board cozy with equity grants despite the bleeding. The company’s survival may hinge on converting 'strategic cooperation' into hard revenue, but with negative cash flow and thin liquidity, the market waits for substance over press releases.
Chart-wise, PASW’s recent news has done little to arrest its liquidity challenges. The stock’s trading volume and market cap (not explicitly listed but implied by equity of $6.4M) suggest a frigid aftermarket. Without a buyback program or clear path to profitability, the share price remains at the mercy of news-driven volatility rather than fundamentals.
The evidence remains thin on tangible outcomes from PASW’s partnerships. While the Yuan Sheng Mei Yan deal headlines, the absence of financial specifics or timelines leaves investors with more hope than data. The next catalyst could be regulatory approvals or a cash influx, but until then, the balance sheet tells a story of a company living off the vapors of announcements.
Sources & evidence · 9 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
PASW technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on PASW
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep PASW research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
PASW FAQ
What is Ping An Biomedical Co., Ltd. (PASW)?Ping An Biomedical Co., Ltd. (PASW) has a latest verified close of 0.131, up 1.55%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Ping An Biomedical Co., Ltd. (PASW) has a latest verified close of 0.131, up 1.55%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for PASW?Ping An Biomedical Co., Ltd. (PASW) has a latest verified close of 0.131, up 1.55%, dated 6 Aug 2026. It brings the latest available chart, company context, cited...
Ping An Biomedical Co., Ltd. (PASW) has a latest verified close of 0.131, up 1.55%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files PASW under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the PASW page updated?The PASW public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The PASW public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for PASW?The PASW file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:PASW. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The PASW file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:PASW. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on PASW?Yes. The workstation can open PASW, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open PASW, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this PASW page investment advice?No. The PASW page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The PASW page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →